Payments from pharmaceutical companies to physicians are pervasive and associated with poorer-quality prescribing and increased health care costs.1 Little is known about payments to nonprescribing clinicians, despite their vital role in patient care, medication management, and health care administration.2 Assumptions persist among clinicians and policy makers that marketing to nonphysicians is inconsequential because they do not prescribe3; however, emerging evidence suggests that nurses and pharmacists frequently interact with sales representatives.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Karanges EA, Grundy Q, Bero L. Understanding the Nature and Extent of Pharmaceutical Industry Payments to Nonphysician Clinicians. JAMA Intern Med. Published online June 10, 2019179(10):1430–1432. doi:10.1001/jamainternmed.2019.1371
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: